Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 2d. Annual reported cases of notifiable diseases, by region and reporting area, United States and U.S. Territories, excluding Non-U.S. Residents*, 2019†
Data from some jurisdictions may be incomplete due to the coronavirus disease 2019 (COVID-19) pandemic. Please see Note #9 at the bottom of the table.
Reporting Area Brucellosis Campylobacteriosis Candida auris, clinical § Carbapenemase-producing carbapenem-resistant Enterobacteriaceae Chancroid Chlamydia trachomatis infection
U.S. Residents, excluding U.S. Territories 165 71,509 175 1,483 8 1,808,703
New England 2 3,493 — 15 3 61,914
Connecticut — 734 — — — 15,290
Maine — 191 — — — 3,989
Massachusetts 2 1,732 — — 3 31,622
New Hampshire — 302 — — — 3,577
Rhode Island — 355 — 15 — 5,718
Vermont — 179 — — — 1,718
Middle Atlantic 16 10,132 — 61 — 223,907
New Jersey 1 1,996 — — — 37,591
New York (excluding New York City) 3 2,488 — — — 48,696
New York City 5 2,908 — 61 — 75,926
Pennsylvania 7 2,740 — — — 61,694
East North Central 8 9,331 170 462 — 261,019
Illinois 5 2,541 170 — — 81,012
Indiana 1 1,065 — 271 — 35,430
Michigan 1 1,651 — 162 — 50,104
Ohio — 2,442 — — — 65,393
Wisconsin 1 1,632 — 29 — 29,080
West North Central 9 6,593 — 8 — 107,934
Iowa 2 1,391 — — — 16,044
Kansas — 790 — — — 15,286
Minnesota 4 1,492 — — — 24,470
Missouri 1 1,348 — — — 34,416
Nebraska 2 811 — — — 9,291
North Dakota — 237 — — — 3,880
South Dakota — 524 — 8 — 4,547
South Atlantic 27 11,754 5 730 1 391,469
Delaware 5 208 — — — 5,864
District of Columbia 1 133 — — — 9,327
Florida 8 4,525 N N — 110,794
Georgia 5 1,380 1 262 — 67,720
Maryland 2 892 3 — 1 37,779
North Carolina 1 1,997 1 249 — 70,257
South Carolina 2 553 — — — 35,950
Virginia 3 1,641 — 219 — 48,169
West Virginia — 425 — — — 5,609
East South Central 6 3,403 — 71 2 118,531
Alabama 4 750 N N — 31,228
Kentucky — 1,127 — — 2 20,911
Mississippi — 601 — 71 — 25,303
Tennessee 2 925 — — — 41,089
West South Central 54 7,959 — — — 205,920
Arkansas 3 719 — — — 17,196
Louisiana 5 871 — — — 36,131
Oklahoma 2 1,191 — — — 23,518
Texas 44 5,178 — — — 129,075
Mountain 10 5,525 — 100 1 129,869
Arizona 2 1,615 — 77 1 43,058
Colorado 2 1,245 — — — 29,821
Idaho 2 551 — — — 6,863
Montana — 372 — — — 4,753
Nevada 2 237 — 9 — 17,827
New Mexico 1 688 — — — 14,283
Utah 1 581 — 12 — 11,075
Wyoming — 236 — 2 — 2,189
Pacific 33 13,319 — 36 1 308,140
Alaska 1 129 — — — 6,254
California 23 9,790 — 4 1 236,719
Hawaii 6 401 — 2 — 8,093
Oregon — 1,020 — — — 19,279
Washington 3 1,979 — 30 — 37,795
Territories 1 46 3 49 — 6,918
American Samoa — — — — — 81
Commonwealth of Northern Mariana Islands — — — — — 249
Guam 1 13 3 — — 1,234
Puerto Rico — 33 — 49 — 4,817
U.S. Virgin Islands — — — — — 537
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
  • U: Unavailable — The data are unavailable.
  • * The 2019 annual tables exclude cases of nationally notifiable conditions and diseases among non-U.S. residents. As a result, data in Table 2 does not include a "Non-U.S. Resident" or "Total" row, that would have been included in the table had the data been stratified into the following four categories, based upon the "country of usual residence" (COUR) algorithm: U.S. Residents, excluding U.S. Territories; U.S. Territories; Non-US. Residents; and Total.Table 2 for the 2019 annual tables only includes the first two of these stratification categories.
  • † To calculate rates, use the populations provided in Table 8. Note that calculation of rates for the following conditions use population subsets presented in Table 8: Zika virus infection, congenital; Zika virus disease, congenital; Infant botulism; Congenital rubella syndrome; Perinatal Hepatitis B infection, Perinatal Hepatitis C infection, Haemophilus influenzae, invasive disease and Invasive pneumococcal disease, and Influenza associated pediatric mortality; see Table 8 (population reference table). Also see notes 3 and 7.
  • § Candida auris colonization/screening cases are not included in this table. These data are available on the Mycotic Diseases Branch's Tracking Candida auris page (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html)
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  2. The list of national notifiable infectious diseases and conditions for 2019 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2019" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2018 by CSTE for national surveillance that were implemented in January 2019. Candida auris, clinical became a new national notifiable condition, and revised case definitions were implemented for the following conditions: diphtheria, acute hepatitis A, listeriosis, yellow fever, Salmonella Paratyphi infection and Salmonella Typhi infection. Salmonella Paratyphi infection and Salmonella Typhi infection replaced Paratyphoid fever and Typhoid fever, respectively, as national notifiable conditions. Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) replaced Salmonellosis (excluding paratyphoid fever and typhoid fever) as a national notifiable condition. In addition, Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) represents a consolidation of CP-CRE species Klebsiella spp, CP-CRE E. coli, and CP-CRE Enterobacter spp. Publication criteria for the finalized 2019 data are available at https://wonder.cdc.gov/nndss/documents/2019_NNDSS _Publication_Criteria_01212021.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2019, estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010, to July 1, 2019, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2019), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released July 9, 2020, are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2019 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on August 6, 2020, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2021. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks, select "Annual Reports" in the "Genre" box to the left).
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal Hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months)
    • Perinatal Hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2019 (National Center for Health Statistics Natality 2019, as compiled from data provided by the Vital Statistics Cooperative Program). The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Congenital syphilis data are published in Syphilis Statistics in the sexually transmitted diseases (STD) surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) and in the historical archives of the STD surveillance report (https://www.cdc.gov/std/stats/archive.htm). The STD surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) updates congenital syphilis cases and rates over time.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. The following 24 jurisdictions may have incomplete data, due to the coronavirus disease 2019 (COVID-19) pandemic: Alaska, California, Connecticut, Delaware, District of Columbia, Florida, Idaho, Indiana, Kansas, Massachusetts, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New York (excluding New York City), New York City, North Dakota, Ohio, Oklahoma, South Carolina, Tennessee, Texas, and West Virginia. In addition, the following 2 U.S. Territories may have incomplete data due to the COVID-19 pandemic: American Samoa and the U.S. Virgin Islands.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.